TrilliumBio, Oncobit Partner to Offer Uveal Melanoma Monitoring Test in the US

Original from: genomeweb

Diagnostics firm TrilliumBio said Tuesday that it is collaborating with Oncobit to offer the Swiss company's uveal melanoma monitoring assay in the US. 

Under the partnership, financial details of which were not disclosed, Rockville, Maryland-based TrilliumBio will make Oncobit's CE-marked and IVDR-certified digital PCR-based Oncobit Personalized Monitoring (PM) test available through its laboratory. 

Oncobit PM detects cancer hot-spot mutations associated with cutaneous and uveal melanoma in the BRAF, NRAS, GNAQ, GNA11, and SF3B1 genes in circulating tumor DNA. The results provide minimal residual disease (MRD) information to support therapy decisions and predict treatment response and progression. 

"We're excited that patients in the US will now have access to Oncobit's uveal melanoma solution through this partnership," Claudia Scheckel, CEO of Zurich-based Oncobit, said in a statement. "By expanding availability to next-generation diagnostics for this uncommon cancer, we're helping patients and families navigate their care while building momentum for new biomarkers, indications, and the future of precision oncology."

Source: TrilliumBio, Oncobit Partner to Offer Uveal Melanoma Monitoring Test in the US